oxidopamine has been researched along with Cortical Lewy Body Disease in 2 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, Y | 1 |
| Zhu, JH | 1 |
| Kulich, SM | 1 |
| Oury, TD | 1 |
| Chu, CT | 1 |
2 other studies available for oxidopamine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Editorial for the Special Issue "Animal Models of Parkinson's Disease and Related Disorders".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Early Diagnosis; Huma | 2020 |
Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases.
Topics: Aged; Aged, 80 and over; Animals; Catalase; Cell Fractionation; Cell Line; Cytoplasm; Humans; Lewy B | 2002 |